A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. [electronic resource]
Producer: 20020418Description: 303-8 p. digitalISSN:- 0149-5992
- Anti-Obesity Agents -- economics
- Cardiovascular Diseases -- mortality
- Cost-Benefit Analysis
- Diabetes Mellitus, Type 2 -- complications
- Humans
- Hypercholesterolemia -- drug therapy
- Hypertension -- economics
- Lactones -- economics
- Markov Chains
- Models, Econometric
- Obesity -- complications
- Orlistat
- Risk Factors
- Time
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.